bioSyntagma has been awarded “Best Oncology-Focused Precision Medicine Company 2018” by Global Health and Pharma, a UK-based publication that recognizes global companies for improving public health, enhancing patient care, and lowering healthcare costs. This award follows several commercial milestones with strategic partners and Big Pharma using bioSyntagma’s beta-instruments to offer biomarker discovery services. Striving to eliminate-trial-and-error cancer treatments through predictive analytics and novel diagnostic tools, bioSyntagma has developed a suite of AI-enabled technologies that collectively create the Molecular Fingerprint™. “The Molecular Fingerprint (mPrint) is how personalized medicine transitions
Phoenix, AZ (October 30, 2018) – The Arizona Commerce Authority (ACA) today announced 25 semifinalists in the Fall 2018 round of the Arizona Innovation Challenge, a bi-annual business plan competition for promising early-stage companies in high-growth industries. As many as ten recipients in each round will receive up to $150,000 each in capital to grow their businesses, advancing innovation and technology commercialization opportunities in Arizona. The funding for each awardee will be released in phases, according to milestones that are defined by participation in the Venture Ready
Phoenix, AZ (March 20, 2018) — bioSyntagma, a precision medicine company, has been awarded a nearly $200,000 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop a new platform for mapping multi-omic biomarkers from single-cells in cancer patient biopsies. bioSyntagma’s Principal Scientist, Dmitry Derkach, M.D., Ph.D., is the Principal Investigator for the project. The award provides funding to develop a spatial, multi-omic single-cell analysis platform that can provide vast amounts of information about
Phoenix, AZ (February 6, 2019 — bioSyntagma, LLC, a developer of life science tools for single and multi-cell analysis announced today it has been has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant of $735,139. Upon completion of the Phase I SBIR, bioSyntagma successfully demonstrated feasibility of their technology, the LightStream FloCellTM, which visually maps genetic information across a tissue and correlates this information with molecular measurements in a high-throughput and automated fashion, with the ultimate goal of enabling personalized medicine. Phase II funding
Phoenix, AZ — bioSyntagma, LLC announced today that the United States Patent and Trademark Office fully issued patent # 15/099,121 for “Method and Apparatus for Extracting and Collecting Single Cells from Formalin-Fixed Paraffin Embedded Tissues,” which bioSyntagma has exclusively licensed from Arizona Technology Enterprises (AzTE). This patent is the foundational technology for the company’s unique microfluidic chip technology, the Light Stream FloCell™. The LightStream FloCell™ allows researchers to examine patient and research tissues to understand how disease-causing cells interact with each other. bioSyntagma’s technology is seen as fundamental